


Atty Docket No.: R0067D DIV
 USSN: 10/685,124

CLAIM LISTING

Claims 1-41 (canceled)

42. (Currently Amended) A compound of Formula I



wherein:

R^1 , R^2 and R^3 are independently in each occurrence hydrogen, halogen, (C_{1-6}) -alkyl, $-OR'$, $-SR'$, $-NR'R''$, $-SOR'$, $-SO_2R'$, $-COOR'$, $-OCOR'$, $-OCONR'R''$, $-OSO_2R'$, $-OSO_2NR'R''$, $-NR'SO_2R''$, $-NR'COR''$, $-SO_2NR'R''$, $-SO_2(CH_2)_{1-3}CONR'R''$, $-CONR'R''$, cyano, haloalkyl, or nitro; or R^1 and R^2 if adjacent, taken together with the carbons to which they are attached may also form a 5- to 7- membered aromatic, saturated or unsaturated ring, optionally incorporating one or two ring heteroatoms chosen from N, S (O)₀₋₂, or O, and optionally substituted with (C_{1-6}) -alkyl, halo, cyano or lower alkoxy;

R' and R'' are independently in each occurrence hydrogen, (C_{1-6}) -alkyl, substituted lower alkyl, (C_{0-3}) alkylalkoxy, aryl, heterocyclyl, heteroaryl, aryl- (C_{1-3}) -alkyl, heteroaryl- (C_{1-3}) -alkyl, heterocyclyl- (C_{1-3}) -alkyl, cycloalkylalkyl, cycloalkyl, or R' and R'' together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S(O)₀₋₂;

R^4 is independently in each occurrence (C_{1-6}) alkyl;

R^5 is independently in each occurrence (C_{1-6}) alkyl, (C_{1-6}) alkenyl, (C_{1-6}) alkynyl, or cycloalkyl;

one of X, Y or Z is independently S, O, or $N-R^6$, the others are CH_2 ;

R^6 is hydrogen, (C_{1-6}) -alkyl, haloalkyl, aryl- (C_{1-6}) alkyl, heteroaryl- (C_{1-6}) alkyl, $-(C_{1-6})-CR'R'R'$, $-COOR'$, $-SO_2R'$, $-C(O)R'$, $-SO_2(CH_2)_{0-3}NR'R''$, $-CONR'R''$, $-C(O)OCH_2OC(O)R'$, $-C(O)OCH_2SC(O)R'$, or $-PO(OR')_2$, where R' and R'' are as defined above;

m is 1;

Atty Docket No.: R0067D DIV
USSN: 10/685,124

n is 3 ~~an integer from 1 to 6 inclusive~~;
or pharmaceutically acceptable salts or solvates thereof.

43. (Canceled)
44. (Previously Presented) The compound of Claim 42, wherein R⁴ is methyl.
45. (Canceled)
46. (Previously Presented) The compound of Claim 42, wherein X is S or O.
47. (Previously Presented) The compound of Claim 42, wherein Y is S or O.
48. (Previously Presented) The compound of Claim 42, wherein Z is S or O.
49. (Previously Presented) The compound of Claim 42, wherein one of X, Y or Z is NR⁶ and the others are CH₂.
50. (Previously Presented) The compound of Claim 49, wherein X is NH.
51. (Previously Presented) The compound of Claim 49, wherein Y is NH.
52. (Previously Presented) The compound of Claim 49, wherein Z is NH.
53. (Previously Presented) The compound of claim 42, wherein X is S, O, or N-R⁶, and Y and Z are CH₂.
54. (Currently Amended) The compound of claim 4[[3]]2, wherein X is S or O, and Y and Z are CH₂.

Atty Docket No.: R0067D DIV
USSN: 10/685,124

55. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 42 in admixture with a pharmaceutically acceptable carrier.
56. (Canceled)
57. (Previously Presented) A method for treating a subject suffering from detrusor hyperactivity ~~a smooth-muscle-function disease~~ mediated by an M2/M3 muscarinic receptor antagonist, said method comprising administering to said subject an effective amount of at least one compound of claim 42.
58. (Canceled)
59. (Canceled)